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Peroxisome proliferator-activated receptors are ligand-activated transcription factors belonging to the nuclear hormone receptor
superfamily. PPARs regulate several metabolic pathways by binding to sequence-speciﬁc PPAR response elements in the promoter
regionoftargetgenes,includinglipidbiosynthesisandglucosemetabolism.Recently,PPARsandtheirrespectiveligandshavebeen
implicated as regulators of cellular inﬂammatory and immune responses. These molecules are thought to exert anti-inﬂammatory
eﬀects by negatively regulating the expression of proinﬂammatory genes. Several studies have demonstrated that PPAR ligands
possess anti-inﬂammatory properties and that these properties may prove helpful in the treatment of inﬂammatory diseases of the
lung. This review will outline the anti-inﬂammatory eﬀects of PPARs and PPAR ligands and discuss their potential therapeutic
eﬀects in animal models of inﬂammatory lung disease.
Copyright © 2007 R. Di Paola and S. Cuzzocrea. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. PPARs: OVERVIEW
PPARs are members of the nuclear hormone receptor su-
perfamily that were initially characterized as molecules that
mediated the proliferation of peroxisomes in rodent liver
parenchymal cells in response to the hypolipidemic drug
cloﬁbrate [1]. Subsequently, PPARs have been shown to reg-
ulate the expression of genes involved in a variety of biolog-
ical processes, including lipid metabolism and insulin sensi-
tivity [2, 3]. Three isotypes of PPAR exist, PPAR-α (alpha),
PPAR-β/δ (beta/delta), and PPAR-γ (gamma), which are en-
coded by three separate genes and display distinctly diﬀerent
tissue distributions and functions. PPAR-γ, like other PPAR
isotypes, exists as a heterodimer complexed with the retinoid
X receptor and several corepressor molecules that tonically
suppress PPAR activity [4]. In the presence of PPAR ligands,
corepressor molecules are shed, followed by association of
coactivator proteins, binding to speciﬁc PPAR-response el-
ements, and transcription of target genes [4] (see Figure 1).
PPAR-α is activated by polyunsaturated fatty acids and
synthetic ﬁbrates, and is implicated in regulation of lipid
metabolism, lipoprotein synthesis and metabolism, and in-
ﬂammatory response in liver and other tissues. PPAR-α is
highly expressed in tissues with high fatty acid oxidation
(such as liver, kidney, and heart muscle), where it controls
a comprehensive set of genes that regulate most aspects of
lipid catabolism. Like several other nuclear hormone recep-
tors,PPAR-αheterodimerizeswithRXRalphatoformatran-
scriptionally competent complex [5]. In addition, PPAR-α
is expressed in vascular endothelial cells, smooth muscle
cells, monocyte/macrophages, and T lymphocytes. Activa-
tion of PPAR-α in selected cellular systems increases HDL
cholesterol synthesis, stimulates “reverse” cholesterol trans-
port, and reduces triglycerides [6].
T h eb i o l o g i c a lr o l eo fP P A R - β/δ has not been clearly de-
ﬁned.AnimalstudiesrevealedthatPPAR-β/δ playsanimpor-
tant role in the metabolic adaptation of several tissues to en-
vironmental changes. Treatment of obese animals with spe-
ciﬁcPPAR-β/δ agonistsresultsinnormalizationofmetabolic
parameters and reduction of adiposity. PPAR-β/δ was also
implicated in the regulation of fatty acid burning capacities
of skeletal muscle and adipose tissue by controlling the ex-
pression of genes involved in fatty acid uptake, beta oxida-
tion, and energy uncoupling. Moreover, PPAR-β/δ has been2 PPAR Research
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Figure 1: Schematic of PPAR activation events. Like other nuclear hormone receptors, PPAR acts as a ligand-activated transcription factor.
PPAR-α, when activated after binding with speciﬁc ligand, interacts with RXR and regulates the expression of target genes. These genes are
also involved in the catabolism of fatty acids. Conversely, PPAR-γ is activated by diﬀerent ligands (e.g., prostaglandins, leukotrienes, and
antidiabetic thiazolidinediones) and regulates the expression of genes involved in the storage of the fatty acids. PPAR-β is only weakly acti-
vated by fatty acids, prostaglandins, and leukotrienes and has no known physiologically relevant ligand. Abbreviations: nuclear corepressor
protein: (NcoR); PPAR gamma coactivator 1:(PGC-1); histone acyltransferase: (HAT); steroid receptor coactivator-1: (SR-1); 9-cis retinoic
acid: (RA).
shown to mediate the adaptive metabolic response of skeletal
muscle to endurance exercise by controlling the number of
oxidative myoﬁbers and stimulating fatty acid catabolism in
muscular tissue [7]. Recent studies revealed that ligand ac-
tivation of these receptors is associated with improved in-
sulin sensitivity and elevated HDL levels thus demonstrating
promising potential for targeting PPAR-β/δ in the treatment
of obesity, dyslipidemias, and type 2 diabetes [8].
PPAR-γ plays an important role in the regulation of pro-
liferation and diﬀerentiation of several cell types, including
adipose cells. This receptor has the ability to bind a variety of
small lipophilic compounds derived from both metabolism
and nutrition. These ligands, in turn, direct cofactor recruit-
ment to PPAR-γ, regulating the transcription of genes in a
variety of complex metabolic pathways. PPAR-γ is highly ex-
pressed in adipocytes, where it mediates diﬀerentiation, pro-
motes lipid storage, and, as a consequence, is thought to
indirectly improve insulin sensitivity and enhance glucose
disposal in adipose tissue and skeletal muscle [9, 10]. Acti-
vation by drugs of the glitazone (thiazolidinediones) group
results in insulin sensitization and antidiabetic action. Nat-
urally occurring lipids can also activate PPAR-γ, including
arachidonic, oleic, and linoleic acid, and the cyclopentenone
prostaglandin (PG) 15-deoxy Delta12,14-PGJ2 (15d-PGJ2), a
metaboliteofprostaglandinD2.Nitosylatedoleicandlinoleic
acid species have more recently been identiﬁed as potent
PPAR-γ agonists at concentrations present in human tissues.
The cellular expression proﬁle of PPAR-γ in pulmonary tis-
sue has not been well characterised, but studies have uncov-
ered abundant expression of PPAR-γ in airway epithelium
[11], bronchial submucosa [12], in mononuclear phagocytes
such as human alveolar macrophages (AM), human T lym-
phocytes, and in several pulmonary cell lines, including hu-
man bronchial and alveolar epithelial cells (NL20, BEAS, and
A549 [13]) and human airway smooth muscle (HASM) cells
[14].TheexpressionofthevariousisotypesofPPARishighly
cell speciﬁc. For instance, HASM cells express PPAR-α and
PPAR-γ,b u tn o tP P A R - β/δ, whereas primary normal hu-
man bronchial epithelial cells and human lung epithelial cell
lines BEAS 2B, A549, and NCI-H292 all express PPAR-γ and
PPAR-β/δ,b u tn o tP P A R - α [15]. Because little is known re-
garding the role of PPAR-β/δ in regulating inﬂammation, es-
pecially in the context of lung injury, this review will focus
on the biology of PPAR-α and PPAR-γ in human and animal
models of acute lung injury (ALI).
2. ACUTE LUNG INJURY (ALI)
Injury to the lung can occur in response to a variety of pul-
monary and extrapulmonary insults. In humans, ALI and its
more severe form, the acute respiratory distress syndrome
(ARDS) are syndromes of acute respiratory failure, which
are deﬁned clinically on the basis of both radiographical
(bilateral lung ﬁeld inﬁltrates) and physiological (the ratio
of arterial oxygen pressure and the inspiratory oxygen con-
centration, Pa/Fi ≤ 300mmHg for ALI and ≤ 200mmHg
for ARDS) criteria. These syndromes occur as a result of
widespread damage to cells and structures of the alveo-
lar capillary membrane and evolve within hours to days
[16]. ALI/ARDS can develop as a consequence of critical
illness of diverse etiologies, including direct injury to lung
suchaspneumonia,aspiration,toxicinhalation,neardrown-
ing, or lung contusion; as well as indirect mechanisms,
such as sepsis, burn injury, pancreatitis, gynecological insultsR. Di Paola and S. Cuzzocrea 3
Acute lung injury
Gastric aspiration
Hemorrhage
Pneumonia
Near drowning
Infection
Shock
Trauma
Burns
Transfusion
Neutrophil activation iNOS
Nitric oxide
Peroxinitrite
DNA single strand break
PARP activation
ATP depletion
Cellular dysfunction Pulmonary dysfunction
Tissue injury
Super oxide
Figure 2: Pathophysiological events in acute lung injury.
(abruption of placenta, amniotic embolism, eclampsia), or
massive blood transfusion [17].
The pathophysiological consequences of ALI/ARDS are
related to the altered pulmonary capillary permeability and
alveolar diﬀusion capacity, as well as the increased intra-
pulmonary shunt. Endothelial injury and increased vascu-
lar permeability is a central feature of ALI/ARDS, and some
but not all studies suggest a role for neutrophils in mediat-
ing endothelial injury [17, 18]. Epithelial injury is also im-
portant not only in the development but also the repair of
the ALI/ARDS [19]. The degree of epithelial injury can pre-
dict outcome of ALI/ARDS [20]. Loss of epithelial integrity
and injury to type II alveolar cells can disrupt the normal
ﬂuid transport, thereby impairing the removal of ﬂuid from
the alveolar space. Injury to the type II pneumocytes can
reduce the production of surfactant, which contributes to
the clinical course of worsening atelectasis and gas exchange.
The process of epithelial repair can be dysregulated, leading
to proliferation of ﬁbroblasts, exuberant matrix deposition
and remodeling, and culminate in ﬁbrosis [21, 22]. There
arecomplexautocrineandparacrineinterrelationshipsofcy-
tokines, as well as proinﬂammatory mediators that initiate
and amplify the inﬂammatory response in ALI/ARDS. The
cellular responses include the expression of endothelial ad-
hesion molecules, as well as the margination and migration
of neutrophils and other inﬂammatory cells. A number of
soluble factors are released that contribute to the pathobiol-
ogy of ALI/ARDS, including cytokines, lipid mediators, pro-
teases, oxidants, growth factors (e.g., transforming growth
factors (TGFs)), nitric oxide (NO), and neuropeptides [23]
(see Figure 2). This inﬂammatory state is driven by the acti-
vation of several key-signalling pathways including the NF-
κB, AP-1 and the mitogen-activated protein kinase (MAPK)
pathways.
2.1. PPAR-αandlunginjury
Based on both in vivo and in vitro studies in multiple cell
systems, PPAR-α ligands have important anti-inﬂammatory
properties. For example, treatment of an activated murine
macrophage cell line with the synthetic PPAR-α ago-
nist Wy14643 [peroxisome proliferation-activated receptor-
alpha (PPAR-alpha) activator, 4-cholro-6-(2.3-xylidino)-2-
pyrimidinaylthio acetic acid] resulted in inhibition of nitric
oxide synthase (NOS), whereas LTB4 and 8(S)-HETE, two
natural PPAR-α ligands, stimulated the expression of nitric
oxide synthase (NOS) activity in these same cells [24]. The
authors have postulated that this disparity resulted from low
potency and speciﬁcity of the endogenous ligands in com-
parison with that of synthetic compounds [25]. The in vivo
role of PPAR-α in the regulation of inﬂammatory/immune-
related functions is less well studied. The ﬁrst in vivo ev-
idence for the role of PPAR-α evolved from studies using
PPAR-α deﬁcient mice [26]. These mice are viable, but ex-
hibit altered triglyceride and cholesterol metabolism and
fail to respond to appropriate PPAR-α ligands. Data gener-
ated using PPAR-α knockout mice indicate that this recep-
tor regulates acute inﬂammation in vivo [27]. For exam-
ple, PPAR-α-deﬁcient mice have abnormally prolonged re-
sponsestodiﬀerentinﬂammatorystimuli[28].Furthermore,
ﬁbrates have anti-inﬂammatory properties in vitro [29]a n d
in vivo [30]. In particular, PPAR-α ligands can inhibit the
expression of several proinﬂammatory genes such as IL-6,
VCAM, and cyclooxygenase-2, in response to cytokine acti-
vation [30]. Moreover, the suppressive eﬀect of PPAR-α lig-
ands is mediated by inhibition of NF-κB activation, in part
by enhancing the expression of IκBα [31]. It is important to
note that synthetic and natural PPAR-α agonists can exert
multiple biologic eﬀects, including some which occur in a4 PPAR Research
PPAR-α-independent fashion [32]. WY14643, like GW7647,
shows excellent selectivity for murine and human PPAR-α.
Recent investigations have addressed the contribution
of PPAR-α to the development of acute pleural and pul-
monary inﬂammation and injury. We reported that when
compared with wild-type mice, PPAR-α knockout mice ex-
perienced more severe pleural inﬂammation when subjected
to intrapleural carrageenan administration. Speciﬁcally, the
absence of a functional PPAR-α gene resulted in a signiﬁ-
cant augmentation of several inﬂammatory parameters (e.g.,
pleuralexudateformation,mononuclearcellinﬁltration,and
histological injury). Furthermore, PPAR-α−/− mice had en-
hanced the expression of tumor necrosis factor alpha (TNF-
α), interleukin-1 beta (IL-1β), and FAS ligand in the pleural
space post carrageenan administration [33].
Agonists for PPAR-α have been shown to reduce lipo-
polysaccharide (LPS)- and cytokine-induced secretion of
matrix metalloproteinase-9 (MMP-9) in human monocytes
and rat mesangial cells, suggesting that this nuclear hormone
receptor may play a beneﬁcial role in controlling both tissue
inﬂammation and remodeling. Consistent with this notion,
Delayre-Orthez showed enhanced airway neutrophil and
macrophage inﬁltration, elaboration of TNF-α, chemokines,
a n dM M P9i nP P A R - α−/− mice challenged with intranasal
LPS, compared to that observed in similarly treated PPAR-
α+/+ mice. Conversely, pretreatment with the PPAR-α ag-
onist fenoﬁbrate reduced LPS-medicated airway inﬂamma-
tion, cytokine/chemokine expression and MMP-2 and -9 ac-
tivity in bronchoalveolar lavage ﬂuid [34]. Our laboratory
has investigated the role of PPAR-α ligands in acute pul-
monary inﬂammation using an experimental model of acute
pancreatitis induced by cerulein. Intraperitoneal administra-
tion of cerulein in PPAR-α deﬁcient mice resulted in severe
inﬁltration of pancreatic and lung tissue with neutrophils
(as measured by changes in myeloperoxidase activity), and
enhanced expression of the adhesion molecules intercellular
adhesion molecule-1 (ICAM-1), P-selectin, and growth fac-
tors TGF-β and VEGF in lung tissue, as compared to that
observed in wild-type animals [35]. Interestingly, Jiang et al.
haverecentlyshownthatacutelunginjuryinratsinresponse
to LPS results in a reduced expression of PPAR-α mRNA and
protein in the lung, raising the possibility that alterations in
PPAR-αexpression/activitymaycontributetoheightenedin-
ﬂammatory response [36].
S i m i l a rt oe ﬀects in other models of pulmonary injury,
PPAR-α appears to play a pivotal role in regulating the in-
ﬂammatory response in experimental models of bleomycin-
induced acute lung injury. Intratracheal administration of
bleomycin in PPAR-α−/− mice resulted in a signiﬁcant aug-
mentation of TNF-α,I L - 1 β, and immunoreactive poly-ADP-
ribose, as well as a loss of body weight and increased mor-
tality. The dysregulated expression of poly-ADP-ribose is of
particular relevance, as this molecule is synthesized from
nicotinamide adenine dinucleotide (NAD) by poly-ADP ri-
bose polymerase (PARP) during periods of oxidative stress,
and enhanced PARP activity results in consumption of
NAD+, ATP depletion, and ultimately cellular dysfunction.
Conversely, the treatment of wild-type mice with WY14643
(1mg/kg daily) prior to bleomycin administration signiﬁ-
cantly reduced the degree of lung injury, attenuated the rise
in bleomycin-induced myeloperoxidase activity, and reduced
the expression of TNF-α,I L - 1 β , and poly-ADP-ribose [37].
2.2. PPAR-γ andlunginjury
In contrast to genetic models of PPAR-α deﬁciency, studies
evaluating immunomodulatory eﬀects of PPAR-γ have been
limited by the absence of mice that are homozygous deﬁcient
for PPAR-γ, as these fetuses die in utero. For that reason,
most studies assessing the role of PPAR-γ in inﬂammatory
responses in vivo have relied on treatment with PPAR-γ ago-
nists and/or antagonists or the use of mice that are heterozy-
gous PPAR-γ deﬁcient mice (PPAR-γ+/−), which display re-
duced but not absence PPAR-γ activity.
As previously noted, the cyclopentenone prostaglandin
15d-PGJ2 functions as an endogenous ligand for PPAR-γ.
We reported that 15d-PGJ2 (given at 10, 30, or 100μg/kg
IP) in the carrageenan-induced pleurisy model exerted po-
tent anti-inﬂammatory eﬀects (e.g., inhibition of pleural ex-
udate formation, mononuclear cell inﬁltration, delayed de-
velopment of clinical indicators, and histological injury) in
vivo.Furthermore,15d-PGJ2 reducedtheincreaseinnitroty-
rosine and poly (ADP-ribose) polymerase and the expres-
sion of inducible nitric-oxide synthase and cyclooxygenase-
2, as determined by immunohistochemistry, in the lungs
of carrageenan-treated mice [38]. We also observed that
rosiglitazone (given at 3, 10, or 30mg/kg IP 15 minutes
before carrageenan administration in the pleurisy model)
exerted similar anti-inﬂammatory eﬀects (e.g., inhibition
of pleural exudate formation, mononuclear cell inﬁltra-
tion, and histological injury) in vivo as that observed with
15d-PGJ2. Furthermore, rosiglitazone reduced: (1) the in-
crease in nitrotyrosine and poly (ADP-ribose) polymerase
(PARP); (2) the expression of inducible nitric oxide syn-
thase (iNOS), cyclooxygenase-2 (COX-2), intercellular adhe-
sion molecules-1 (ICAM-1), and P-selectin in the lungs of
carrageenan-treated rats. In order to elucidate whether the
protective eﬀect of rosiglitazone was causally related to ac-
tivation of PPAR-γ, we investigated the eﬀect of a PPAR-γ
antagonist, bisphenol A diglycidyl ether (BADGE), on the
protective eﬀects of rosiglitazone. BADGE (30mg/kg IP) ad-
ministered 30 minutes prior to treatment with rosiglitazone
signiﬁcantly antagonized the suppressive properties of the
PPAR-γ agonist [39].
In an animal model of severe haemorrhage and resus-
citation, Abdelrahman et al. investigated the eﬀects of 15d-
PGJ2 administration on the development of multiple organ
injury/dysfunction. Importantly, PPAR-γ agonist 15d-PGJ2
abolished the renal dysfunction and largely reduced the liver
injury caused by hemorrhagic shock. In addition, 15d-PGJ2
attenuated lung and intestinal injury (as determined by his-
tology) caused by haemorrhage and resuscitation [40].
We investigated the eﬀects of rosiglitazone on the de-
velopment of nonseptic shock caused by zymosan in mice.
Treatment of mice with rosiglitazone (3mg/kg IP, 1 and 6
hours after zymosan) attenuated the peritoneal exudationR. Di Paola and S. Cuzzocrea 5
and the migration of polymorphonuclear cells caused by zy-
mosan. Rosiglitazone also attenuated zymosan-induced lung
dysfunction, as well as the increase in myeloperoxidase activ-
ity and malondialdehyde concentrations in the lung. To elu-
cidatewhethertheprotectiveeﬀectsofrosiglitazoneoccurred
in a PPAR-γ speciﬁc fashion, we investigated the eﬀect of a
PPAR-gamma antagonist, GW9662, on the protective eﬀects
of rosiglitazone. GW9662 (1mg/kg administered IP 30 min-
utes before treatment with rosiglitazone) signiﬁcantly abol-
ished the protective eﬀect of rosiglitazone [41].
There exists convincing evidence that treatment with
PPAR-γ agonists can also modulate pulmonary inﬂamma-
tion and tissue injury in response to systemic LPS admin-
istration and ischemia-reperfusion injury. For instance, ex-
perimental endotoxemia for 4 hours induced histological ev-
idence of lung injury and edema formation, both of which
were signiﬁcantly attenuated by rosiglitazone pretreatment.
T h ep r o t e c t i v ee ﬀects of rosiglitazone were correlated with
the reduction by 71% and 84%, of the increase of myeloper-
oxidaseandmalondialdehyde,respectively,inthelungtissue.
Furthermore, the pulmonary induction of nitric oxide was
reduced by 82% of the increase related to lipopolysaccharide
[42].Morerecently,ithasbeenshownthatpreischemictreat-
ment with pioglitazone, a synthetic ligand of PPAR-γ, signif-
icantly attenuated ischemia/reperfusion (I/R)-induced lung
injury in rats, including reductions in lung microvascular
permeability, lipid peroxidation, tissue-associated polymor-
phonuclear leukocyte inﬁltration, and proinﬂammatory cy-
tokine production. These ﬁndings can be explained, at least
in part, by PPAR-γ-mediated inhibition of transcription fac-
tors such as NF-κB[ 43], resulting in attenuated cytokine,
chemokine and eicosanoid production, adhesion molecule
expression, and as a consequence reduced inﬂammatory cell
inﬂux and injury to the alveolar capillary [44–47]. Another
mechanism of protection aﬀorded by the PPAR-γ agonist
troglitazoneinI/Rlunginjuryissuppressionoftranscription
factor early growth response gene-1 and its inﬂammatory
gene targets such as interleukin-1β, monocyte chemotactic
protein-1, and macrophage inﬂammatory protein-2 [48].
While the majority of studies have found potent anti-
inﬂammatory properties of PPAR-γ agonists, observations
made in several studies challenge this paradigm. Notably,
Inoue et al. [49] demonstrated that pretreatment of mice
with 15d-PGJ2 did not reduce pulmonary inﬂammation
induced by intratracheal LPS administration. In fact, at
the highest concentrations (1mg/kg), 15d-PGJ2 paradoxical-
lyenhanced LPS-induced alveolar inﬂammation, pulmonary
edema, and inﬂammatory cytokine expression. One possible
explanation for the observed disparity in results may be at-
tributable to PPAR-independent eﬀects of selected agonists,
dose-dependent toxicity or diﬀerences in the model systems
used. The role of PPAR-γ in acute lung inﬂammation was
also investigated in ﬂuorescein isothiocyanate-treated mice.
Here, pretreatment with pioglitazone (vehicle by oral gav-
age daily for 5 days) decreased the number of neutrophils
recovered in bronchoalveolar lavage (BAL) by 50% 3 days
after intratracheal challenge with ﬂuorescein isothiocyanate.
However, the decreased pulmonary inﬂammation was not
associated withinhibition of the expression of inﬂamma-
tory cytokines (TNF-α, macrophage inﬂammatory protein-
2, KC, IL-12, or IFN-γ) in either BAL ﬂuidor whole lung
homogenates [50]. The authors speculated that the possi-
ble mechanism by which a PPAR-γ ligand suppresses inﬂam-
mation in the absence of changes in cytokine expressionwas
by a direct eﬀect on migration of neutrophils (and possibly
other leukocytes) in response to endogenous chemoattrac-
tants [50]. In the FITC model, treatment with pioglitazone
alsohadonlymodestsuppressiveeﬀectsonalveolar-capillary
leakorsubsequentﬁbroproliferation.Thedisparateeﬀectsof
PPAR-γ agonists on inﬂammation relative to alveolar capil-
lary injury and repair may be attributable to direct eﬀects of
PPAR-γ activation on alveolar epithelial cells. Treatment of
A549 alveolar type II-like epithelial cells with 15d-PGJ2 or
TZDs, or forced expression of a constitutively active PPAR-
γ has been shown to suppress NF-κB transcriptional activity
and decreased inﬂammatory cytokine and chemokine pro-
duction. However, incubation of these cells with PPAR-γ lig-
ands also suppressed alveolar epithelial cell proliferative re-
sponses. Collectively these data suggest that beneﬁcial anti-
inﬂammatory properties of PPAR-γ in ALI may be partially
oﬀset by growth inhibitory eﬀects on alveolar epithelial cells,
responses that are necessary for repair of an injured alveolar-
capillary membrane.
Orderly lung remodeling is required for restoration of
an intact alveolar-capillary membrane after injury. Fibrob-
lasts are one of the key eﬀector cells in this process. How-
ever, the diﬀerentiation of ﬁbroblasts to myoﬁbroblasts can
result in excessive and uncontrolled production of collagen
and other extracellular matrix components, leading to ﬁbro-
sis. Importantly, PPAR-γ agonists have been shown to block
two of the most important proﬁbrotic activities of TGF-β
on pulmonary ﬁbroblasts; myoﬁbroblast diﬀerentiation and
production of excess collagen. Both natural (15d-PGJ2)a n d
synthetic (ciglitazone and rosiglitazone) PPAR-γ agonists in-
hibited TGF-β-driven myoﬁbroblast diﬀerentiation in hu-
man lung ﬁbroblasts, as determined by alpha-smooth mus-
cle actin expression. PPAR-γ agonists also potently attenu-
atedTGF-β-induced type Icollagenprotein production [51].
Transfection with a dominant-negative PPAR-γ construct
partially reversed the inhibition of myoﬁbroblast diﬀeren-
tiation by 15d-PGJ2 and rosiglitazone, but the irreversible
PPAR-γ antagonist GW-9662 did not, suggesting that the an-
tiﬁbroticeﬀectsofthePPAR-γ agonistsaremediatedthrough
both PPAR-γ-dependent and independent mechanisms.
Observations made in several studies suggest that the ac-
tivation of PPAR-γ may exert both anti-inﬂammatory and
antiﬁbroticeﬀectsinvivo.Micesubjectedtointratrachealad-
ministration of bleomycin develop marked lung injury fol-
lowed by ﬁbrosis. An increase in immunoreactivity to ni-
trotyrosine, poly (ADP ribose) polymerase (PARP), and in-
ducible nitric oxide synthase as well as a signiﬁcant loss
of body weight and mortality was observed in the lung of
bleomycin-treated mice. Administration of the two PPAR-
gamma agonists rosiglitazone (10mg/kg IP) or 15d-PGJ2
(30μg/kg IP) signiﬁcantly reduced: (1) the loss of body
weight; (2) mortality rate; (3) inﬁltration of the lung with6 PPAR Research
polymorphonuclear neutrophils (myeloperoxidase activity);
(4) edema formation; (5) histological evidence of lung injury
and ﬁbroproliferation; and (6) nitrotyrosine, PARP, and in-
ducible nitric oxide synthase formation [52]. Pretreatment
with the PPAR-gamma competitive antagonist BADGE sub-
stantially mitigated the eﬀect of the two PPAR-gamma ag-
onists, indicating a PPAR-γ speciﬁc response. Our ﬁndings
are in agreement with Ando et al. [53], who demonstrated
that the intravenous injection of prostaglandin D synthase
(PGDS) cDNA-expressing ﬁbroblasts signiﬁcantly reduced
lung edema, BAL leukocytes, and pulmonary collagen 4
weeksafterintratrachealinstillationofbleomycin.Moreover,
this attenuated lung response to bleomycin was quite similar
to that seen in animals pretreated with 15d-PGJ2, the nonen-
zymatic metabolite of PGD2, suggesting that these naturally
occurring ligands exert relevant eﬀects on the ﬁbroprolifera-
tive response in vivo.
3. CONCLUSION
The subsequent tissue response to acute and chronic lung in-
jury involves an intricate series of events including immune
cell inﬁltration, release of injurious host-derived molecules
such as reactive oxygen and nitrogen species, and high per-
meability edema formation. In addition, ﬁbroproliferative
repair is characterized by myoﬁbroblast transdiﬀerentiation
and the deposition of extracellular matrix proteins. Failure
to initiate, maintain, or stop this repair program has dra-
m a t i cc o n s e q u e n c e ss u c ha sc e l ld e a t ho re x u b e r a n tw o u n d
repair. PPARs appear to be critical regulators of host inﬂam-
matory and reparative responses, and these transcriptional
factors may be activated by lipid mediators produced in re-
sponse to lung injury. The generation of better transgenic
model systems, including conditional and site-speciﬁc trans-
genic mouse models, are required to more precisely deﬁne
the contribution of PPAR-γ a n do t h e rP P A Rf a m i l ym e m -
bers to disease pathogenesis in ALI and other inﬂammatory
lung diseases. This class of nuclear hormone receptors may
serve as important targets for therapeutic intervention in the
treatment of patient with both acute and chronic inﬂamma-
tory disorders of the lung.
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